Avrupa Birliği - Almanca - EMA (European Medicines Agency)

astrazeneca ab - saxagliptin - diabetes mellitus, typ 2 - drogen bei diabetes verwendet - add-on combination therapyonglyza is indicated in adult patients aged 18 years and older with type-2 diabetes mellitus to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy:in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control;in combination with a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate;in combination with a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate;as triple oral therapy:in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control;as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

Avrupa Birliği - Almanca - EMA (European Medicines Agency)

astrazeneca ab - benralizumab - asthma - medikamente für obstruktive atemwegserkrankungen, - fasenra ist angezeigt als add-on erhaltungstherapie bei erwachsenen patienten mit schwerem eosinophilen asthma nicht ausreichend kontrolliert, trotz hoher dosis, inhalative corticosteroide plus langwirksame β-agonisten.

Avrupa Birliği - Almanca - EMA (European Medicines Agency)

astrazeneca ab - natrium-zirkonium cyclosilicate - hyperkaliämie - alle anderen therapeutischen produkte - lokelma ist indiziert für die behandlung von hyperkalaemia bei erwachsenen patienten.

Avrupa Birliği - Almanca - EMA (European Medicines Agency)

astrazeneca ab - glycopyrronium, formoterol fumarate dihydrate - lungenerkrankung, chronisch obstruktiv - formoterol und glycopyrronium bromid - bevespi aerosphere angegeben ist eine wartung bronchodilatator-behandlung zur linderung der symptome bei erwachsenen patienten mit chronisch-obstruktiver lungenerkrankung (copd).

Avrupa Birliği - Almanca - EMA (European Medicines Agency)

astrazeneca ab - andexanet alfa - medikament-nebenwirkungen und nachteilige reaktionen - alle anderen therapeutischen produkte - für erwachsene patienten, die mit einem direkten faktor-xa - (fxa) - hemmer (apixaban oder rivaroxaban) bei der umkehrung der antikoagulation erforderlich ist wegen lebensbedrohender oder unkontrollierte blutungen.

Avrupa Birliği - Almanca - EMA (European Medicines Agency)

astrazeneca ab - formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - lungenerkrankung, chronisch obstruktiv - medikamente für obstruktive atemwegserkrankungen, - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.

Avrupa Birliği - Almanca - EMA (European Medicines Agency)

astrazeneca ab - acalabrutinib - leukämie, lymphozytär, chronisch, b-zell - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.

Avrupa Birliği - Almanca - EMA (European Medicines Agency)

astrazeneca ab - moxetumomab pasudotox - leukämie, haarige zelle - antineoplastische mittel - lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (hcl) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (pna).

Avrupa Birliği - Almanca - EMA (European Medicines Agency)

astrazeneca ab - tixagevimab, cilgavimab - covid-19 virus infection - prevention of covid-19.

Avrupa Birliği - Almanca - EMA (European Medicines Agency)

astrazeneca ab - anifrolumab - lupus erythematodes, systemisch - immunsuppressiva - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.